SELECT * FROM `stock_list` where symbol='CSL' AND exchange = 'ASX' limit 0,1
SELECT * FROM `stock_list` where symbol='CSL' AND exchange = 'ASX' limit 0,1
SELECT * FROM `stock_list` WHERE `symbol` = "CSL" and stock_list.exchange IN (SELECT exchange FROM gurufocu_main.stock_list_exchanges where country='USA' and active=1) limit 0,1 CSL (ASX:CSL) Deferred Policy Acquisition Costs
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CSL Ltd (ASX:CSL) » Definitions » Deferred Policy Acquisition Costs

CSL (ASX:CSL) Deferred Policy Acquisition Costs


View and export this data going back to 1994. Start your Free Trial

What is CSL Deferred Policy Acquisition Costs?

Deferred Policy Acquisition Costs only applies to banks and insurance companies.


CSL (ASX:CSL) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CSL Ltd (ASX:CSL) » Definitions » Deferred Policy Acquisition Costs
Traded in Other Exchanges
Address
655 Elizabeth Street, Melbourne, VIC, AUS, 3000
CSL is one of the largest global biotech companies and has two main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders and neurological indications. Seqirus is now the world's second largest influenza vaccination business and was acquired in fiscal 2015. CSL has a strong R&D track record, and the product portfolio and pipeline include non-plasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe.